万泰生物(603392) - 2025 Q2 - 季度业绩预告

2025 Semi-Annual Pre-Loss Announcement Current Period Performance Forecast The company anticipates a shift from profit to loss in the first half of 2025, with estimated net profit attributable to shareholders ranging from -RMB 160 million to -RMB 130 million, and non-recurring net profit from -RMB 260 million to -RMB 230 million, based on unaudited figures 2025 Semi-Annual Performance Forecast | Indicator (2025 Semi-Annual Estimate) | Amount (RMB) | | :--- | :--- | | Net Profit Attributable to Parent Company Shareholders | -160 million to -130 million | | Net Profit Attributable to Parent Company Shareholders (Excluding Non-Recurring Items) | -260 million to -230 million | - The performance forecast covers the period from January 1, 2025, to June 30, 2025[3] - This performance forecast has not been audited by a certified public accountant[4] Prior Period Performance Review The announcement provides 2024 comparative earnings data, showing a net profit attributable to shareholders of RMB 260 million, non-recurring net profit of RMB 63.52 million, and basic earnings per share of RMB 0.21 for the first half of 2024 2024 Semi-Annual Performance | Indicator (2024 Semi-Annual) | Amount (RMB) | | :--- | :--- | | Total Profit | 258.15 million | | Net Profit Attributable to Parent Company Shareholders | 260.48 million | | Net Profit Attributable to Parent Company Shareholders (Excluding Non-Recurring Items) | 63.52 million | | Earnings Per Share | 0.21 | Analysis of Main Reasons for Pre-Loss The pre-loss is primarily due to short-term sales pressure in two core business segments: vaccines, impacted by policy adjustments and market competition, and IVD, affected by government procurement price reductions and unbundling of testing packages - Vaccine segment: Revenue and profit significantly declined year-on-year due to industry policy adjustments and intensified market competition[7] - IVD (In Vitro Diagnostics) segment: Short-term sales revenue faced pressure due to factors such as government centralized procurement price reductions and unbundling of testing packages[7] Risk Warning The company confirms no significant uncertainties exist that could affect the accuracy of this performance forecast as of the announcement date - The company states there are no significant uncertainties affecting the accuracy of this performance forecast[8] Other Explanations The company emphasizes that the disclosed financial data are preliminary, with final accurate figures subject to the official 2025 semi-annual report, advising investors to be aware of investment risks - The forecast data are preliminary, and the final accurate financial data will be subject to the company's officially disclosed 2025 semi-annual report[9]